Gene Therapy For Parkinson's Disease Global Market Report 2025

Description

Gene therapy for Parkinson's disease involves using genetic techniques to introduce, repair, or regulate genes within brain cells. The therapy aims to restore dopamine production, protect nerve cells, or correct disease-related mutations, with the goal of slowing disease progression and providing long-term symptom relief.

The primary therapy types of gene therapy for Parkinson's disease are in vivo gene therapy and ex vivo gene therapy. In vivo gene therapy involves the direct delivery of genetic material into the patient's body, typically using viral or non-viral vectors, to restore or enhance the function of specific genes associated with Parkinson's disease. Target genes include aromatic L-amino acid decarboxylase (AADC), glial cell line-derived neurotrophic factor (GDNF), neurturin, and other related genes. These therapies are administered via intracerebral, intravenous, and other delivery methods. Key end-users include hospitals, specialty clinics, research institutes, and related healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The gene therapy for parkinson's disease market research report is one of a series of new reports from The Business Research Company that provides gene therapy for parkinson's disease market statistics, including the gene therapy for parkinson's disease industry global market size, regional shares, competitors with the gene therapy for parkinson's disease market share, detailed gene therapy for parkinson's disease market segments, market trends, and opportunities, and any further data you may need to thrive in the gene therapy for parkinson's disease industry. This gene therapy for parkinson's disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gene therapy for parkinson's disease market size has grown exponentially in recent years. It will grow from $0.51 billion in 2024 to $0.64 billion in 2025 at a compound annual growth rate (CAGR) of 26.5%. The growth in the historic period is attributed to the increasing prevalence of Parkinson's disease, rising demand for personalized therapies, growing awareness of gene therapy, expansion of clinical trial networks, and higher funding for neurodegenerative research.

The gene therapy for parkinson's disease market size is expected to see exponential growth in the next few years. It will grow to $1.62 billion in 2029 at a compound annual growth rate (CAGR) of 26.1%. The growth in the forecast period is driven by greater adoption of viral vector-based therapies, increased investment in gene therapy startups, rising government support for rare disease treatments, expansion of research collaborations, and development of healthcare infrastructure in emerging markets. Key trends in the forecast period include technological advancements in viral delivery systems, innovations in neurotrophic factor therapies, development of targeted gene-editing constructs, increased research and development investment, and progress in precision medicine approaches.

The increasing interest in personalized medicine is expected to drive the growth of the gene therapy for Parkinson's disease market. Personalized medicine is a healthcare approach that customizes treatment and prevention strategies based on an individual's genetic profile, lifestyle, and environmental factors. Interest in this approach continues to rise due to growing demand for targeted therapies that enhance treatment effectiveness and reduce unwanted side effects. In the context of Parkinson's disease, gene therapy supports personalized medicine by delivering tailored genetic modifications that aim to restore dopamine function and address unique disease mechanisms specific to each patient. For example, in February 2024, the Personalized Medicine Coalition, a nonprofit organization based in the United States, reported that in 2023, the United States Food and Drug Administration approved sixteen new personalized treatments for rare disease patients, up from six approvals in 2022. As a result, the growing interest in personalized medicine is contributing to the expansion of the gene therapy for Parkinson's disease market.

Companies operating in the gene therapy for Parkinson's disease market are actively developing more precise treatments such as regenerative medicine advanced therapies to promote neuron survival, restore dopamine production, and provide durable disease-modifying benefits for individuals with Parkinson's disease. Regenerative medicine advanced therapy is a designation granted by the United States Food and Drug Administration to regenerative medicine products, including cell and gene therapies as well as tissue-engineered products, that aim to treat, reverse, or cure serious or life-threatening conditions. For example, in February 2025, Asklepios BioPharmaceutical Inc., a gene therapy company based in the United States, introduced AB-1005, an experimental gene therapy using adeno-associated virus to deliver glial cell line-derived neurotrophic factor. This therapy received regenerative medicine advanced therapy designation from the FDA. The designation was based on clinical data from a Phase Ib open-label, uncontrolled trial, which demonstrated AB-1005's potential to slow the progression of Parkinson's disease and improve motor function.

In January 2025, BlackfinBio Limited, a company based in the United Kingdom that specializes in clinical-stage gene therapy for rare neurological and dopamine-related disorders, acquired the Parkinson's disease patent portfolio from Oxford Biomedica plc for an undisclosed amount. With this acquisition, BlackfinBio aims to further develop its BFB-201 program for Parkinson's disease and benefit from Oxford Biomedica's intellectual property in gene and cell therapy to accelerate therapeutic innovation. Oxford Biomedica plc is a company based in the United Kingdom that develops gene and cell therapies and provides vector technologies, offering valuable expertise and intellectual assets.

Major players in the gene therapy for parkinson's disease market are Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.

North America was the largest region in the gene therapy for parkinson's disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gene therapy for parkinson's disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gene therapy for parkinson's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gene therapy for parkinson's disease market consists of revenues earned by entities by providing services such as genetic counseling, preclinical studies, clinical trial management, and personalized treatment planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The gene therapy for parkinson's disease market also includes sales of viral vectors, aromatic L-amino acid decarboxylase (AADC) gene therapy, glutamic acid decarboxylase (GAD) gene therapy, glial cell line-derived neurotrophic factor (GDNF) or neurturin-based neurotrophic therapies, and glucocerebrosidase (GBA)-targeted gene therapies. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gene Therapy For Parkinson's Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gene therapy for parkinson's disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gene therapy for parkinson's disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gene therapy for parkinson's disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Therapy Type: In Vivo Gene Therapy; Ex Vivo Gene Therapy
2) By Vector Type: Viral Vectors; Non-Viral Vectors
3) By Target Gene: Aromatic L-Amino Acid Decarboxylase (AADC); Glial Cell Line-Derived Neurotrophic Factor (GDNF); Neurturin; Other Target Genes
4) By Delivery Method: Intracerebral; Intravenous; Other Delivery Methods
5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End-Users
Subsegments:
1) By In Vivo Gene Therapy: Viral Vectors; Non-Viral Vectors
2) By Ex Vivo Gene Therapy: Autologous Cell-Based Gene Therapy; Allogeneic Cell-Based Gene Therapy
Companies Mentioned: Merck & Co. Inc.; Bayer AG; Sanofi S.A.; Eli Lilly and Company; Biogen Inc.; PTC Therapeutics Inc.; Zambon S.p.A.; Oxford BioMedica plc; Voyager Therapeutics Inc.; Insilico Medicine Inc.; Spur Therapeutics Inc.; Cerevance Inc.; MeiraGTx Holdings plc; BlackfinBio Inc.; Partner Therapeutics Inc.; Kenai Therapeutics Inc.; CureSen Therapeutics Inc.; BioVie Inc.; Clexio Biosciences Ltd.; Tetraneuron S.L.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r38537

1. Executive Summary

2. Gene Therapy For Parkinson's Disease Market Characteristics

3. Gene Therapy For Parkinson's Disease Market Trends And Strategies

4. Gene Therapy For Parkinson's Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Gene Therapy For Parkinson's Disease Growth Analysis And Strategic Analysis Framework

5.1. Global Gene Therapy For Parkinson's Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Gene Therapy For Parkinson's Disease Market Growth Rate Analysis
5.4. Global Gene Therapy For Parkinson's Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Gene Therapy For Parkinson's Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Gene Therapy For Parkinson's Disease Total Addressable Market (TAM)

6. Gene Therapy For Parkinson's Disease Market Segmentation

6.1. Global Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
In Vivo Gene Therapy
Ex Vivo Gene Therapy
6.2. Global Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Viral Vectors
Non-Viral Vectors
6.3. Global Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Aromatic L-Amino Acid Decarboxylase (AADC)
Glial Cell Line-Derived Neurotrophic Factor (GDNF)
Neurturin
Other Target Genes
6.4. Global Gene Therapy For Parkinson's Disease Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intracerebral
Intravenous
Other Delivery Methods
6.5. Global Gene Therapy For Parkinson's Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Research Institutes
Other End-Users
6.6. Global Gene Therapy For Parkinson's Disease Market, Sub-Segmentation Of In Vivo Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Viral Vectors
Non-Viral Vectors
6.7. Global Gene Therapy For Parkinson's Disease Market, Sub-Segmentation Of Ex Vivo Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Autologous Cell-Based Gene Therapy
Allogeneic Cell-Based Gene Therapy

7. Gene Therapy For Parkinson's Disease Market Regional And Country Analysis

7.1. Global Gene Therapy For Parkinson's Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Gene Therapy For Parkinson's Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gene Therapy For Parkinson's Disease Market

8.1. Asia-Pacific Gene Therapy For Parkinson's Disease Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gene Therapy For Parkinson's Disease Market

9.1. China Gene Therapy For Parkinson's Disease Market Overview
9.2. China Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gene Therapy For Parkinson's Disease Market

10.1. India Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gene Therapy For Parkinson's Disease Market

11.1. Japan Gene Therapy For Parkinson's Disease Market Overview
11.2. Japan Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gene Therapy For Parkinson's Disease Market

12.1. Australia Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gene Therapy For Parkinson's Disease Market

13.1. Indonesia Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gene Therapy For Parkinson's Disease Market

14.1. South Korea Gene Therapy For Parkinson's Disease Market Overview
14.2. South Korea Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gene Therapy For Parkinson's Disease Market

15.1. Western Europe Gene Therapy For Parkinson's Disease Market Overview
15.2. Western Europe Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gene Therapy For Parkinson's Disease Market

16.1. UK Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gene Therapy For Parkinson's Disease Market

17.1. Germany Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gene Therapy For Parkinson's Disease Market

18.1. France Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gene Therapy For Parkinson's Disease Market

19.1. Italy Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gene Therapy For Parkinson's Disease Market

20.1. Spain Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gene Therapy For Parkinson's Disease Market

21.1. Eastern Europe Gene Therapy For Parkinson's Disease Market Overview
21.2. Eastern Europe Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gene Therapy For Parkinson's Disease Market

22.1. Russia Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gene Therapy For Parkinson's Disease Market

23.1. North America Gene Therapy For Parkinson's Disease Market Overview
23.2. North America Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gene Therapy For Parkinson's Disease Market

24.1. USA Gene Therapy For Parkinson's Disease Market Overview
24.2. USA Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gene Therapy For Parkinson's Disease Market

25.1. Canada Gene Therapy For Parkinson's Disease Market Overview
25.2. Canada Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gene Therapy For Parkinson's Disease Market

26.1. South America Gene Therapy For Parkinson's Disease Market Overview
26.2. South America Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gene Therapy For Parkinson's Disease Market

27.1. Brazil Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gene Therapy For Parkinson's Disease Market

28.1. Middle East Gene Therapy For Parkinson's Disease Market Overview
28.2. Middle East Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gene Therapy For Parkinson's Disease Market

29.1. Africa Gene Therapy For Parkinson's Disease Market Overview
29.2. Africa Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gene Therapy For Parkinson's Disease Market Competitive Landscape And Company Profiles

30.1. Gene Therapy For Parkinson's Disease Market Competitive Landscape
30.2. Gene Therapy For Parkinson's Disease Market Company Profiles
- 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Gene Therapy For Parkinson's Disease Market Other Major And Innovative Companies

31.1. PTC Therapeutics Inc.
31.2. Zambon S.p.A.
31.3. Oxford BioMedica plc
31.4. Voyager Therapeutics Inc.
31.5. Insilico Medicine Inc.
31.6. Spur Therapeutics Inc.
31.7. Cerevance Inc.
31.8. MeiraGTx Holdings plc
31.9. BlackfinBio Inc.
31.10. Partner Therapeutics Inc.
31.11. Kenai Therapeutics Inc.
31.12. CureSen Therapeutics Inc.
31.13. BioVie Inc.
31.14. Clexio Biosciences Ltd.
31.15. Tetraneuron S.L.

32. Global Gene Therapy For Parkinson's Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gene Therapy For Parkinson's Disease Market

34. Recent Developments In The Gene Therapy For Parkinson's Disease Market

35. Gene Therapy For Parkinson's Disease Market High Potential Countries, Segments and Strategies

35.1 Gene Therapy For Parkinson's Disease Market In 2029 - Countries Offering Most New Opportunities
35.2 Gene Therapy For Parkinson's Disease Market In 2029 - Segments Offering Most New Opportunities
35.3 Gene Therapy For Parkinson's Disease Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer